C57BL/6N-Agl^{tm1b(EUCOMM)Wtsi}/H

Status	Available to order
EMMA ID	EM:09569
International strain name	C57BL/6N-Agl^{tm1b(EUCOMM)Wtsi}/H
Alternative name	EPD0371_2_E12
Strain type	Targeted Mutant Strains
Allele/Transgene symbol	Agl^{tm1b(EUCOMM)Wtsi}
Gene/Transgene symbol	Agl
Disclaimer	Please note that for EUCOMM and KOMP-CSD mice supplied to the scientific community by INFRAFRONTIER/EMMA: We can not guarantee a null mutation for Knock-out first alleles (tm1a alleles, see http://www.mousephenotype.org/about-ikmc/targeting-strategies) as the critical exon has not been deleted. That the structure of the targeted mutation in the ES cells obtained from EUCOMM/KOMP to generate EUCOMM/KOMP mice is not verified by INFRAFRONTIER/EMMA. It is recommended that the recipient confirms the mutation structure. No check for determining the copy number of the targeting construct in ES cells obtained from EUCOMM/KOMP is done by INFRAFRONTIER/EMMA. The level of quality control before mice are released is to confirm the individual mouse genotype by short range PCR.

Information from provider

Provider	MRC, Medical Research Council
Provider affiliation	Mary Lyon Centre at MRC Harwell
Genetic information	This mouse line originates from EUCOMM ES clone EPD0371_2_E12. For further details on the construction of this clone see the page at the IMPC portal. The critical exon(s) were flanked by loxP sites, and subsequent cre expression excised this critical sequence resulting in a knockout reporter allele (C57BL/6NTac-Tg(ACTB-cre)3Mrt/H). Click here for more information on EUCOMM final vectors.
Phenotypic information	Potential phenotyping data in the IMPC portal
References	None available

Information from EMMA

Archiving centre	Mary Lyon Centre at MRC Harwell, Oxford, United Kingdom

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

Glycogen storage disease due to glycogen debranching enzyme deficiency / Orphanet_366

IMPC phenotypes (allele matching)

decreased bone mineral density / IMPC
tremors / IMPC
cataract / IMPC
abnormal gait / IMPC
increased heart weight / IMPC
increased circulating alanine transaminase level / IMPC
increased circulating alkaline phosphatase level / IMPC
increased kidney weight / IMPC
increased lean body mass / IMPC
increased circulating cholesterol level / IMPC
impaired glucose tolerance / IMPC
increased circulating aspartate transaminase level / IMPC
increased circulating bilirubin level / IMPC
decreased circulating glucose level / IMPC
increased circulating amylase level / IMPC
increased circulating iron level / IMPC
decreased total body fat amount / IMPC
increased circulating creatine kinase level / IMPC
decreased bone mineral content / IMPC
preweaning lethality, incomplete penetrance / IMPC
increased fasting circulating glucose level / IMPC

IMPC phenotypes (gene matching)

increased circulating creatine kinase level / IMPC
increased circulating amylase level / IMPC
increased kidney weight / IMPC
cataract / IMPC
increased lean body mass / IMPC
increased circulating cholesterol level / IMPC
increased circulating alkaline phosphatase level / IMPC
decreased bone mineral content / IMPC
increased fasting circulating glucose level / IMPC
decreased bone mineral density / IMPC
impaired glucose tolerance / IMPC
increased heart weight / IMPC
increased circulating alanine transaminase level / IMPC
abnormal gait / IMPC
decreased total body fat amount / IMPC
tremors / IMPC
increased circulating bilirubin level / IMPC
increased circulating aspartate transaminase level / IMPC
increased circulating iron level / IMPC
preweaning lethality, incomplete penetrance / IMPC
decreased circulating glucose level / IMPC

MGI phenotypes (gene matching)

kyphosis / MGI
hypoglycemia / MGI
abnormal liver morphology / MGI
enlarged liver / MGI
abnormal hepatocyte morphology / MGI
muscle weakness / MGI
hypoactivity / MGI
impaired coordination / MGI
abnormal gait / MGI
premature death / MGI
increased circulating alanine transaminase level / MGI
increased circulating alkaline phosphatase level / MGI
liver fibrosis / MGI
increased circulating aspartate transaminase level / MGI
increased glycogen level / MGI
decreased circulating glucose level / MGI
increased pulmonary respiratory rate / MGI
decreased grip strength / MGI
increased circulating creatine kinase level / MGI
increased liver glycogen level / MGI
increased skeletal muscle glycogen level / MGI
impaired exercise endurance / MGI
decreased fasted circulating glucose level / MGI
increased cardiac muscle glycogen level / MGI
increased brain glycogen level / MGI

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740^*
Rederivation of mice from frozen stock, delivery time available upon request . €3880^*
Tissue - Types of tissue, service fee and delivery time available upon request

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

^* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
MTA will be issued after an order has been submitted.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.

C57BL/6N-Agltm1b(EUCOMM)Wtsi/H